Latest Videos |view all videos
Mayo Clinic scientists propose a breast cancer drug for bladder cancer patients
Amplification of HER2, a known driver of some breast cancers, in a type of bladder cancer called micropapillary urothelial carcinoma (MPUC), has shown that the presence of HER2 amplification is associated with particularly aggressive tumors.
Mayo Clinic expert says heart disease from unnecessarily treating "Low T" serious concern
Low T — health risks of testosterone therapy —- Mayo Clinic. William F. Young Jr., M.D.
Zebrafish Discovery May Shed Light on Human Kidney Function
Researchers say the discovery of how sodium ions pass through the gill of a zebrafish may be a clue to understanding a key function in the human kidney. The findings from a collaboration between Mayo Clinic and the Tokyo Institute of Technology ...
Minority disparities evident in prostate cancer survival rate, Mayo Clinic study shows
A Mayo Clinic study reviewed data on more than 290,000 men with prostate cancer from the past 20 years and found that African-American men are at increased risk of poorer survival rate following prostate cancer treatment compared with other minority groups.
Needle-guided tumor destruction procedures offer near-equivalent lengths of local cancer control compared with surgery for patients with small kidney cancer tumors, according to the results of a large study published in the journal European Urology.
Mayo Clinic researchers help to shine new light on bladder cancer tumors
Mayo Clinic researchers help to shine new light on bladder cancer tumors.
Mayo Clinic Study of Kidney Surgery and Chronic Kidney Disease
Interrupting the blood flow for more than 20 to 25 minutes during kidney cancer surgery leads to a greater risk for patients developing chronic kidney disease
Erectile dysfunction: Harbinger of heart disease?
Charanjit S. Rihal, M.D., and Stephen L. Kopecky, M.D., discuss erectile dysfunction and its impact on cardiovascular prognosis and diagnosis.
Renal denervation — The clues are in the kidney
Robert D. Simari, M.D., and Rajiv Gulati, M.D., Ph.D., discuss the data so far and the ongoing Symplicity-HTN3 trial. Will renal denervation move hypertension into the interventional cardiologists' domain?